The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson & Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have suffered a heart attack. The review was posted on the FDA’s website on Tuesday, two days ahead of a meeting of outside experts who will discuss the drug, also known as rivaroxaban, and recommend whether it should be approved.
Help employers find you! Check out all the jobs and post your resume.
